Loading...

Elicio Therapeutics, Inc.

ELTX•NASDAQ
Healthcare
Biotechnology
$7.85
$0.13(1.68%)

Elicio Therapeutics, Inc. (ELTX) Stock Overview

Explore Elicio Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 68.1/100

Key Financials

Market Cap125.6M
P/E Ratio-1.96
EPS (TTM)$-3.97
ROE8.90%
Fundamental Analysis

AI Price Forecasts

1 Week$8.39
1 Month$4.12
3 Months$1.63
1 Year Target$5.72

ELTX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Elicio Therapeutics, Inc. (ELTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $5.72.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.96 and a market capitalization of 125.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$-3.96
↓ 47.46%
EPS Growth
$-3.96
↑ 38.94%
Operating Margin
0.00%
↓ 25.85%
ROE
890.05%
↓ 47.46%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ELTXAnalyst Recommendations details for ELTX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

CEO

Robert T. Connelly

Employees

32

Headquarters

451 D Street, Boston, MA

Founded

2021

Frequently Asked Questions

;